ReNeuron announces initial pre-clinical data with its ReN003 retinal stem cell
programme and signs collaboration agreement with Schepens Eye Research Institute

Guildford, UK, 4 April 2006:  ReNeuron Group plc (LSE: RENE.L) today announces
initial survival efficacy data with its ReN003 stem cell therapy programme for
diseases of the retina.  The joint research, led by Professors John Greenwood
and Stephen Moss at the UCL Institute of Ophthalmology in London, showed
expansion of human retinal progenitor cells with markers of photoreceptors over
multiple population doublings.   These progenitors showed an ability to engraft
and protect the photoreceptor layer of the retina from degeneration in a retinal
dystrophic model.

The research was funded by a Medical Research Council stem cells strategic
research grant, and will be presented at the Annual Meeting of the Association
for Research in Vision and Ophthalmology (ARVO) in Fort Lauderdale, Florida on
30 April to May 4, 2006.

In order to further its ReN003 retinal stem cell programme, ReNeuron today also
announces that it has entered into a collaborative research agreement with the
Schepens Eye Research Institute at Harvard Medical School, Boston, US. The
research programme under this collaboration will take place in the laboratories
of Dr Michael Young, and aims to establish the key conditions for growing
retinal stem cell lines that can be developed into a scalable, efficacious and
safe therapy that utilises ReNeuron's proprietary c-mycERTAM expansion
technology.  The objective is to develop these stem cell lines to treat major
blindness- causing diseases such as age-related macular degeneration, retinitis
pigmentosa and diabetic retinopathy, which together represent a major unmet
medical need.

Dr John Sinden, Chief Scientific Officer of ReNeuron, said:

'I am delighted that ReNeuron is working so closely with both the UCL Institute
of Ophthalmology and the Schepens, two of the world's major research and
clinical centres in the field of retinal diseases.  Our new collaboration with
Schepens will combine their important patented technology and know-how with
ReNeuron's versatile stem cell platform, with the aim of generating novel stem
cell therapies for these major retinal diseases.  Future collaborations with
both institutions offer the potential to take these therapies through to the
clinic in the most efficient way possible.'...